SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 79,874.00 |
| Book Value / Share | 35.60 |
| Price / Book | n/a |
| NCAV ($M) | -56,208.00 |
| NCAV / Share | -25.05 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.56 |
| Return on Assets (ROA) | 0.31 |
| Return on Equity (ROE) | 0.92 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.67 |
| Current Ratio | 0.86 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 113,943.00 |
| Assets | 250,025.00 |
| Liabilities | 170,151.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 176,954.00 |
| Operating Income | 75,620.00 |
| Net Income | 55,525.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 78,887.00 |
| Cash from Investing | -24,918.00 |
| Cash from Financing | -51,797.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock Inc. | 6.50 | -8.05 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 148,909 | 841,917 | 17.69 | |
| 190,858 | 1,257,243 | 15.18 | |
| 158,843 | 963,081 | 16.49 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABBV – Abbvie Inc | ABT – Abbott Laboratories |
| ADCT – Adc Therapeutics SA | AMRX – Amneal Pharmaceuticals Inc – Class A |
| APN – Apeiron Capital Investment Corp – Class A |
Financial data and stock pages provided by
Fintel.io